New Market Research Report: Analgesics in Denmark

From: Fast Market Research, Inc.
Published: Wed Jun 18 2014

From 1 October 2013, large pack sizes of analgesics were switched from OTC to Rx. More specifically, pack sizes containing more than 10g of acetaminophen or aspirin and more than 4g of ibuprofen can no longer be purchased without a prescription. The change was implemented by the Danish Health and Medicines Authority following research published in British Medical Journal, documenting that a ban on OTC sales of large pack sizes will lead to a reduction in the number of deaths related to analgesics and a declining need for liver transplantations. Leading players reacted positively to the change. GlaxoSmithKline even ran a nationwide campaign in printed media expressing the company's support of the new legislation. With an attitude like this, GlaxoSmithKline and other players managed to present themselves as responsible and concerned about consumers' health and thereby distancing themselves from the negative reputation as greedy profit seekers, which often cling to the medical industry.

Full Report Details at

Competitive Landscape

Analgesics in Denmark was led by Takeda Pharma with value share of 37% in 2013. The company benefits from a wide product selection, which ensures its strong position in all major categories. Thus, it ranked second in acetaminophen and aspirin, while its brand Ipren led ibuprofen.

Industry Prospects

In 2014, the full effect of the switch of large pack sizes to RX will be felt. Parallel to what was witnessed in 2013, total volume sales of analgesics are expected to drop as a part of a sales move to RX and consumers become more aware of the risks related to excessive use of analgesics and therefore reduce their total consumption. The expected volume drop will nevertheless be more than countered by an increase in unit price, as the accepted 20 unit pack sizes have significantly higher prices per pill than the now banned large pack sizes of up to 300 units. The result is a predicted 16% value growth rate in constant 2013 prices for the first year of the forecast period.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Denmark with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in Denmark, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in Denmark market research report includes:

* Analysis of key supply-side and demand trends
* Detailed segmentation of international and local products
* Historic volumes and values, company and brand market shares

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Analgesics in Portugal
- Analgesics in Israel
- Analgesics in Indonesia
- Analgesics in the United Kingdom
- Analgesics in South Korea
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »